Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis  by Kennelly, Michael et al.
Ambulatory and Ofﬁce Urology
Long-term Efﬁcacy and Safety of
OnabotulinumtoxinA in Patients With Urinary
Incontinence Due to Neurogenic Detrusor
Overactivity: An Interim Analysis
Michael Kennelly, Roger Dmochowski, Karen Ethans, Gilles Karsenty,
Heiner Schulte-Baukloh, Brenda Jenkins, Catherine Thompson, Daniel Li, and
Cornelia Haag-Molkenteller
OBJECTIVE To evaluate the long-term efﬁcacy and safety of repeat onabotulinumtoxinA injections inFinancial Disclosure: Writing a
Linda Wychowski, Ph.D., and J
and was funded by Allergan, In
Karsenty, and H. Schulte-Bauklo
received honoraria from Allergan,
Haag-Molkenteller are employees
Funding Support: This study an
From the Carolinas Rehabilitat
TN; University of Manitoba, Wi
Marseille, France; St. Hedwig
Berlin, Germany; Allergan, Inc.
Kingdom
Reprint requests: Michael Ke
Carolinas Rehabilitation, 1100
Michael.Kennelly@carolinashealth
Submitted: June 27, 2012, ac
ª 2013 Elsevier Inc. Opatients inadequately managed by anticholinergics for urinary incontinence (UI) due to neuro-
genic detrusor overactivity.MATERIALS AND
METHODS
Patients who completed either of 2 preceding phase III studies were offered entry into an
extension study and received repeat onabotulinumtoxinA 200 U or 300 U. The data were
integrated across the phase III and ongoing extension studies. The present interim analysis
included all patients who received 1 onabotulinumtoxinA treatment. The data were analyzed
by treatment cycle (cycles 1-5). The primary assessment was the change from baseline in UI
episodes/wk at 6 weeks after each treatment. Additional assessments included 50% and 100%
reductions in UI episodes, volume/void, Incontinence Quality of Life responses, and adverse
events.RESULTS A total of 387, 336, 241, 113, and 46 patients received 1, 2, 3, 4, and 5 onabotulinumtoxinA
treatments, respectively. The UI episodes/wk were consistently reduced compared with baseline
after repeated onabotulinumtoxinA treatment (22.7, 23.3, 23.1, 25.3, and 31.9 for the
200-U onabotulinumtoxinA group in cycles 1-5). The proportion of patients reporting 50%
and 100% (“dry”) reductions from baseline in UI episodes at week 6 ranged from 73%-94% and
36%-55%, respectively. Increases in the mean volume/void (mean increase >130 mL) and
improvements in quality of life were also observed after repeat treatment. The most common
adverse events were urinary tract infections and urinary retention, with no change in the adverse
event proﬁle over time.CONCLUSION The results of our study have shown that repeated onabotulinumtoxinA treatments provide
sustained reductions in UI episodes and increases in the volume/void and quality of life in patients
with neurogenic detrusor overactivity and UI who were inadequately managed by anticholiner-
gics, with no new safety signals. UROLOGY 81: 491e497, 2013.  2013 Elsevier Inc. Open access 
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pen access under CC BY-NC-ND license. neurogenic detrusor overactivity (NDO) in patients who
were not adequately managed by anticholinergics were
ﬁrst demonstrated in 2000 by Schurch et al.1 These initial
results were recently conﬁrmed by 2 pivotal, phase III,
randomized, placebo-controlled, double-blind trials.2,3
Both phase III studies demonstrated that onabotuli-
numtoxinA, administered at a dose of 200 U and 300 U,
signiﬁcantly reduced UI episodes and improved the uro-
dynamic parameters and quality of life (QOL) in patients
with NDO and UI due to spinal cord injury (SCI) or
multiple sclerosis (MS) who were inadequately managed
by anticholinergics (inadequate efﬁcacy or intolerable
side effects). No clinically relevant differences in efﬁcacy
or duration of effect were observed between the 200U and
300 U onabotulinumtoxinA doses, with efﬁcacy lasting
approximately 9-10 mo/injection. Where approved, the0090-4295/13 491
ttp://dx.doi.org/10.1016/j.urology.2012.11.010
200-U dose of onabotulinumtoxinA is the registered
dose for the treatment of patients with UI due to NDO.
OnabotulinumtoxinA is not interchangeable with other
botulinum toxin preparations.
To evaluate the efﬁcacy and safety of repeat injections
of onabotulinumtoxinA in patients with UI due to NDO
resulting from SCI and MS, a prospective, long-term,
open-label, extension study of the phase III clinical
trials was initiated, with patients able to participate for up
to 3 years. This extension study is still ongoing. In the
present study, we report an interim analysis of the results
from the extension study, focusing on the results of
repeated treatment for up to 5 treatment cycles.MATERIAL AND METHODS
Patients and Study Design
Details regarding patient selection and the study designs of the
pivotal phase III trials (the Double-blind InvestiGation of
puriﬁed NeurotoxIn complex in neurogenic deTrusorover-
activitY [DIGNITY] studies) have been previously published
(http://www.clinicaltrials.gov identiﬁers NCT00311376 and
NCT00461292).2,3 In brief, the studies enrolled patients
aged 18 years who had NDO due to SCI or MS with 14 UI
episodes/wk and who were not adequately managed by anti-
cholinergics (inadequate efﬁcacy or intolerable side effects).
Patients who were taking anticholinergics at study entry
continued to take them during the remainder of the 52-week
phase III trials. Patients who completed either of the phase III
studies could enter the long-term, 3-year extension study, in
which they would receive multiple intradetrusor treatments of
onabotulinumtoxinA (http://www.clinicaltrials.gov identiﬁer
NCT00876447). All patients provided written informed
consent, and each participating center obtained institutional
review board or ethics committee approval.
The dose of onabotulinumtoxinA that patients received
during the extension study was the same as the dose the patient
had been randomized to receive in the preceding phase III
studies (200 U or 300 U). The study protocol was amended in
March 2011 such that all patients would receive onabotuli-
numtoxinA 200 U (the registered dose for NDO, where
approved) regardless of whether they had received 200 U or 300
U in the preceding phase III studies. However, the interim data
we report presents the results for both the 200-U and the 300-U
dose groups (ie, the dose to which patients had been randomized
in the phase III studies and also received in the extension study
before the amendment).
Just as in the phase III trials, treatment was administered as
30 injections of 1 mL using cystoscopy (avoiding the trigone)
with either no anesthesia, local anesthesia (with or without
sedation according to local site practice), or general anesthesia.
Patients could receive repeat treatment if the prespeciﬁed repeat
treatment criteria had been fulﬁlled. These included patient
initiation of a request for repeat treatment, a minimum of 12
weeks since the previous study treatment, and 1 UI episode
within 3 days, as recorded in the 3-day patient diary before
a study visit.Safety and Efﬁcacy Assessments
Patients recorded each voiding episode (UI, toilet void, clean
intermittent catheterization [CIC] void) in a bladder diary in492the week preceding each study visit. For one 24-hour period, the
volume of each void was also measured. The patients were
evaluated at weeks 2, 6, and 12 after each treatment.
The primary efﬁcacy measure was the change from study
baseline in the number of weekly UI episodes. The prespeciﬁed
primary point of assessment in each cycle was week 6 after each
treatment, identical to the endpoint in the pivotal studies.
Baseline was deﬁned as the value before any study treatment in
the preceding phase III studies. Additional efﬁcacy variables at
week 6 after each treatment included the proportion of patients
with 50% and 100% reductions from baseline in UI episodes,
a change from baseline in the Incontinence Quality of Life (I-
QOL) total summary scores,4 the I-QOL responder rates
(proportion of patients achieving a 11-point increase from
baseline in I-QOL score), the duration of treatment effect
(interval to patient request for repeat treatment), and the mean
volume/void.
Adverse events (AEs) were also assessed. Urinary tract
infections (UTIs, as reported by the investigators), were deﬁned
as positive urine culture results with a bacteriuria count of >105
colony-forming units/mL in conjunction with a leukocyturia of
>5/high powered ﬁeld or positive urine culture ﬁndings that, in
the investigator’s opinion, required antibiotic therapy. Symp-
tomatic and asymptomatic UTIs were not distinguished. No
predeﬁned deﬁnition was in place for urinary retention in the
study protocol. Therefore, the interpretation of recording
urinary retention as an AE and the need for the initiation of
CIC after treatment were determined by the investigator’s
clinical judgment.
The presence of serum neutralizing antibodies was assessed
using the mouse protection assay5 at baseline (in the preceding
phase III studies), before each treatment, and at study exit.Statistical Analysis
The long-term extension study had no formal statistical power
or sample size calculation because only patients from the
preceding phase III studies could be enrolled. The data from the
patients in the interim analysis of the long-term extension study
were integrated with the corresponding data from the preceding
phase III studies. All patients who received 1 onabotuli-
numtoxinA treatment were included. The data were analyzed by
onabotulinumtoxinA treatment cycle. The present report pres-
ents the efﬁcacy and safety results from an interim analysis
covering 5 treatment cycles.
Efﬁcacy and safety analyses were conducted using the
onabotulinumtoxinA-treated population. The mean changes
from baseline with 95% conﬁdence intervals were calculated for
all efﬁcacy variables. Because the long-term study used 3-day
bladder diaries, weekly UI was calculated as the daily frequency
of incontinence episodes multiplied by 7. Missing values for I-
QOL measures were imputed from multi-item scales. The dura-
tion of treatment effect for each treatment cycle was calculated
according to those patients who requested repeat treatment (and
their repeat treatment request date) and was summarized using
descriptive statistics. De novo (ie, ﬁrst time) catheterization rates
for patients not using CIC at baseline in the phase III studies were
calculated for each treatment cycle. The denominator repre-
sented the number of patients who received onabotulinumtox-
inA in the applicable cycle and had never initiated CIC before
receiving treatment in that cycle, and the numerator represented
the number of patients who initiated CIC for the ﬁrst time during
that cycle.UROLOGY 81 (3), 2013
RESULTS
Baseline Demographics and Disease Characteristics
A total of 387 patients (200-U group, n ¼ 202; 300-U
group, n ¼ 185) were included in the present interim
analysis. Of these patients, 387, 336, 241, 113, 46, 25,
and 9 patients received 1, 2, 3, 4, 5, 6, and 7 onabotu-
linumtoxinA treatments, respectively (Supplemental
Fig. 1). At the point of the present interim analysis,
with data for up to 7 cycles, only 3 of 387 patients had
discontinued because of a lack of efﬁcacy and 5 because of
AEs. Because so few patients had received 6 or 7 treat-
ments when the present interim analysis was performed,
the efﬁcacy and safety results are only presented for
treatment cycles 1-5.
No signiﬁcant differences were found in the baseline
demographics or disease characteristics between the
patients treated with onabotulinumtoxinA 200 U versus
300 U (Supplemental Table 1). The mean patient age
was 46.4 years, 39.8% of patients were men, and 54% of
patients were using anticholinergics. The mean duration
of NDO in the 2 treatment groups was 8 years, and the
mean number of UI episodes/wk at baseline was 31.2.
Efﬁcacy Assessments
The number of UI episodes/wk at week 6 was signiﬁ-
cantly and consistently decreased after repeated onabo-
tulinumtoxinA treatment. The reductions from baseline
were 22.7, 23.3, 23.1, 25.3, and 31.9 in the
200-U dose group and 23.8, 25.0, 23.6, 24.1,
and 29.5 in the 300-U dose group in treatment cycles
1-5, respectively (Fig. 1A). Most patients achieved at
least a 50% reduction from baseline in UI with repeated
onabotulinumtoxinA treatment cycles. The proportion of
patients with at least a 50% reduction in UI episodes
ranged from 73% (lowest, in cycle 4) to 94% (greatest, in
cycle 5). A signiﬁcant proportion of patients were also dry
(100% reduction; Fig. 1B) after onabotulinumtoxinA
treatment. The proportion of dry patients typically ranged
from 36% to 55%, with the exception of the 300-U dose
group in cycle 5, although the latter was considered an
outlier because of the limited number of patients.
Consistent increases were seen from baseline in the
mean volume/void at week 6 in each treatment cycle
(Fig. 1C), with a mean increase of 130 mL (range
133-180) after each onabotulinumtoxinA treatment.
Similarly, the mean I-QOL total summary scores
consistently showed large increases from baseline with
repeated onabotulinumtoxinA treatment. The mean
increase in I-QOL total scores ranged from 27.5 to 44.6,
much larger than the deﬁned minimally important
change of 11 points (Fig. 2A). Most patients (66%-
93% across the 5 treatment cycles) achieved 11-point
increases in total I-QOL scores at 6 weeks after repeated
treatment with onabotulinumtoxinA 200 U or 300 U
(Fig. 2B).
The time to patient request for repeat treatment over
cycles 1 and 2 (which most patients had completed;UROLOGY 81 (3), 2013Supplemental Fig. 1) remained consistent (w250 days or
w36 weeks; Table 1). Because the long-term study is
ongoing, a considerable number of patients (44%-54%)
in the latter treatment cycles (3-5) had not yet requested
or had not yet received their next treatment and were
therefore still continuing in these cycles (Supplemental
Fig. 1). In these latter cycles, a trend toward a slight
reduction in the time to patients’ request for repeat
treatment was observed; however, it is difﬁcult to inter-
pret these results because the cycles are not yet complete.
A full analysis of this parameter can only be provided
once the ﬁnal analysis has been performed when most
treatment cycles have been completed.
Safety Assessments
The AEs occurring in treatment cycles 1-5 are listed in
Table 2. UTIs and urinary retention were the most
common AEs. The incidence of each was similar within
each treatment cycle in patients who received either dose
of onabotulinumtoxinA (200 or 300 U). Speciﬁcally, the
UTI rates for treatment cycles 1-5 were 58.4%, 46.0%,
39.4%, 28.8%, and 20.0% for patients in the 200-U dose
group and 55.1%, 53.1%, 42.1%, 20.4%, and 23.8% in
the 300-U dose group, respectively. The urinary retention
rates for treatment cycles 1-5 were 20.3%, 9.1%, 6.3%,
0%, and 0% for patients in the 200-U dose group and
23.2%, 6.9%, 7.0%, 0%, and 0% for patients in the 300-
U dose group. Again, it should be noted that a consider-
able number of patients in cycles 3-5 have not yet
completed these cycles; therefore, the AE rates reported
for these latter cycles are preliminary.
Of the 86 patients who were not using CIC at baseline
in the phase III trials, the de novo catheterization rate in
the 200-U dose group was 30.0% (26 of 86), 3.8% (2 of
52), 2.9% (1 of 35), 0% (0 of 22), and 0% (0 of 7) in
treatment cycles 1, 2, 3, 4, and 5, respectively. Cumula-
tively, 29 of the 86 patients (33.7%) not using CIC at
baseline before entry into the phase III studies initiated
CIC at some point during the 5 cycles of onabotuli-
numtoxinA treatment. In the 300-U dose group, the
corresponding proportion of patients initiating CIC was
generally greater, with de novo CIC rates of 42.0% (36 of
85), 18.0% (7 of 39), 0%, 0%, and 0% in cycles 1-5.
Overall, 50.6% of patients (43 of 85) initiate CIC at some
point after repeat treatment.
Five patients (3 in the 200-U dose group and 2 in the
300-U dose group) discontinued the study because of
AEs. One discontinuation was treatment-related
(nonserious UTI). No deaths were reported in the
present interim analysis. Of the 387 patients enrolled,
only 1 patient developed toxin-neutralizing antibodies to
onabotulinumtoxinA, which occurred after treatment 6.
The patient (who had SCI) had received frequent repeat
treatment with onabotulinumtoxinA 300 U nearly every
12 weeks. Although this patient’s response was not long
lasting, this patient did demonstrate a treatment response
(ie, 50% reduction in UI episodes from baseline) at
week 6 for treatment cycles 1, 2, 4, and 5 (the week 6493
Figure 1. (A) Change from baseline in weekly urinary incontinence (UI) episodes, (B) proportion of patients who achieved
a 50% reduction or 100% reduction (total continence) of UI episodes, and (C) change from baseline in volume/void at week
6 after each treatment with onabotulinumtoxinA (onabotA). Data presented as mean  95% conﬁdence interval.diary was missing for treatment cycle 3). During treat-
ment cycle 6, when the patient tested positive for
neutralizing antibodies, the patient was a nonresponder at
the week 6 point but had responded again at week 12.
This patient discontinued participation in the study
owing to lack of efﬁcacy.494COMMENT
Two recent, placebo-controlled, double-blind, phase III
studies demonstrated that a single onabotulinumtoxinA
treatment signiﬁcantly reduced the UI episodes
and improved urodynamic parameters and QOL in
patients with UI due to SCI or MS. The efﬁcacy lastUROLOGY 81 (3), 2013
Figure 2. (A) Change from baseline in incontinence quality
of life (I-QOL) total summary scores and (B) proportion of
patients achieving minimal important difference (11-point
increase) in I-QOL at week 6 after each treatment with
onabotulinumtoxinA (onabotA).
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.approximately 9-10 months.2,3 The present results have
demonstrated that onabotulinumtoxinA is effective in
the long term with repeated treatments in these patients
who were inadequately managed by anticholinergics,
without the emergence of new safety signals. The results
are from a large cohort of patients with UI due to NDO
who received multiple onabotulinumtoxinA treatments.
More than 100 patients have received 4 onabotuli-
numtoxinA treatments and nearly 50 patients have
received 5 onabotulinumtoxinA treatments.
A sustained, consistent, and clinically relevant reduc-
tion occurred in the number of weekly UI episodes across
the 5 treatment cycles, with signiﬁcant reductions from
baseline (before any treatment) observed after each ona-
botulinumtoxinA treatment. In addition, approximately
40% of patients experienced a 100% reduction in UI
episodes atweek 6 in each treatment cycle. These results are
consistent with those from the phase III studies,2,3 indi-
cating that a proportion of patients are able to experience
continencewith repeated onabotulinumtoxinA treatment.
OnabotulinumtoxinA treatment also continued to
improve the ability of the bladder to store urine (the
essential bladder function), as evidenced by the consistent
increases in volume/void across the 5 treatment cycles.
Substantial and clinically meaningful improvements in
QOL were observed after cycles 1-5 of onabotuli-
numtoxinA treatment. Approximately 70%-90% ofUROLOGY 81 (3), 2013 495
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496patients achieved improvements greater than the re-
ported minimally important difference of 11 points on
the total I-QOL instrument.6 These results are consistent
with those of the recent phase III studies, which showed
signiﬁcant QOL improvements after a single treatment
with onabotulinumtoxinA.2,3
The duration of effect was durable for the ﬁrst 2
treatment cycles (for which most patients had completed
the cycles); however, for the remaining cycles, in which
44%-55% of patients were still ongoing, a slight reduction
in the time to patient request for repeat treatment was
seen. This reduction was possibly because many patients
in the later treatment cycles (after cycle 3) were still
ongoing and had not yet requested or received their next
treatment. It also is possible that once patients experi-
enced reductions in their UI and improvements in QOL
with onabotulinumtoxinA treatment, they might not
accept the recurrence of UI episodes and might therefore
request repeat treatment earlier. A thorough analysis of
this parameter will only be possible once more treatment
cycles have been completed and the 3-year extension
study has ﬁnished.
Repeat treatments with onabotulinumtoxinA were
well tolerated, and the AE proﬁle remained comparable
across the treatment cycles. Just as in the preceding phase
III onabotulinumtoxinA trials, the most frequently re-
ported AE was UTI. The rates we observed were
comparable to those reported in the phase III trials.2,3
However, the rates in both the 200-U and 300-U dose
groups appeared similar, unlike in the phase III trials in
which the UTI rates were higher in the 300-U dose
group, especially in the MS population. The UTI rates in
the present analysis were also consistent with the rates
reported in a large cohort of patients with NDO.7 In
patients who were not using CIC at baseline, de novo
CIC occurred most often after the ﬁrst onabotuli-
numtoxinA treatment. However, some patients initiated
CIC after the second or third injection. Many patients
did not initiate CIC after repeated treatments, with some
of these patients receiving 4 or 5 onabotulinumtoxinA
injections. Overall, just over 40% of the patients not
using CIC at baseline initiated CIC at some point after
repeat treatment. However, because the analysis of the
phase III trial results demonstrated that most patients not
using CIC were predominantly patients with MS,2,3 it was
difﬁcult to differentiate de novo CIC purely due to ona-
botulinumtoxinA treatment vs de novo CIC resulting
from additional impairment of voiding function from the
underlying progressive disease. Because the long-term
study is ongoing, the ﬁnal analysis will provide a more
complete analysis of these data.
The incidence of neutralizing antibody formation was
low after repeat onabotulinumtoxinA injections. Only 1
patient developed neutralizing antibodies to onabotuli-
numtoxinA, in treatment cycle 6 after frequent treatment
with 300 U, with injections nearly every 12 weeks. As
previously reported, the relationship between the pres-
ence of neutralizing antibodies and treatment responseUROLOGY 81 (3), 2013
has not been established.8-10 However, some studies have
suggested that the frequency of onabotulinumtoxinA
injections and higher doses might lead to a greater inci-
dence of antibody formation.9,11
One limitation of these results is that they were from
an interim analysis, which has only reported the safety
and efﬁcacy parameters up to the cutoff date. The eval-
uations are ongoing in the long-term study and will
further characterize the safety and efﬁcacy proﬁle of
onabotulinumtoxinA in this patient population.
CONCLUSION
Sustained reductions in UI episodes and improvements in
QOL were observed with repeated treatments with ona-
botulinumtoxinA in patients with UI due to NDO who
were inadequately managed by anticholinergics. The
safety proﬁle was consistent with that reported in the
phase III trials with onabotulinumtoxinA, with no new
safety signals observed with repeat treatment.
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